Simon Spazzapan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9058901/publications.pdf

Version: 2024-02-01

73	1,676	393982	301761
papers	citations	19 h-index	39 g-index

78	78	78	2646
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clinical Cancer Research, 2022, 28, 308-317.	3.2	36
2	How palliative care professionals deal with predicting life expectancy at the end of life: predictors and accuracy. Supportive Care in Cancer, 2021, 29, 2093-2103.	1.0	4
3	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.	0.9	14
4	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 791958.	2.2	2
5	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Research, 2020, 22, 83.	2.2	6
6	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. Annals of Oncology, 2020, 31, S304-S305.	0.6	7
7	Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study. European Journal of Cancer, 2020, 138, S63.	1.3	0
8	Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. Cancers, 2020, 12, 1005.	1.7	5
9	Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy. , 2020, , .		0
10	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptorâ€“Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology, 2019, 37, 105-114.	0.8	72
11	Ten daily fractions for partial breast irradiation. Long-term results of a prospective phase II trial. Breast Journal, 2019, 25, 243-249.	0.4	6
12	Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		15
13	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews, 2019, 72, 7-14.	3.4	25
14	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. Journal of Clinical Oncology, 2019, 37, 577-577.	0.8	0
15	Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Annals of Oncology, 2018, 29, 881-887.	0.6	7
16	Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiotherapy and Oncology, 2018, 126, 177-180.	0.3	116
17	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018, 379, 122-137.	13.9	448
18	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Annals of Oncology, 2017, 28, 2225-2232.	0.6	56

#	Article	IF	Citations
19	Seven fractions to deliver partial breast irradiation: the toxicity is Low. Radiation Oncology, 2017, 12, 86.	1.2	4
20	Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Frontiers in Immunology, 2017, 8, 1476.	2.2	54
21	Abstract P2-09-05: 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer. , 2017, , .		0
22	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. British Journal of Cancer, 2016, 114, 956-964.	2.9	38
23	PO-0675: Radical radiotherapy in ologometastatic breast cancer patients. Radiotherapy and Oncology, 2016, 119, S315.	0.3	0
24	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Journal of Translational Medicine, 2015, 13, 204.	1.8	64
25	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS ONE, 2015, 10, e0136731.	1.1	11
26	Idarubicin. Reactions Weekly, 2015, 1538, 128-128.	0.0	0
27	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncology, The, 2015, 16, 848-858.	5.1	145
28	Five Year Results With 3-D Conformal Radiation Therapy to Deliver Partial-Breast Irradiation Consisting of 40 Gy in 10 Daily Fractions. International Journal of Radiation Oncology Biology Physics, 2015, 93, E33.	0.4	0
29	Quality of Life, Pain Perception, and Distress Correlated toÂUltrasound-Guided Peripherally Inserted Central Venous Catheters in Palliative Care Patients in a Home or Hospice Setting. Journal of Pain and Symptom Management, 2015, 50, 118-123.	0.6	17
30	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). , 2015, , .		2
31	Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. , 2015, , .		2
32	A randomized phase III study of vinflunine versus an alkylating agent of physicianâ€™s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid.. Journal of Clinical Oncology, 2015, 33, 1031-1031.	0.8	6
33	Abstract P5-18-05: The Promher Study: An observational Italian study on HER2+ve, pT1a-b, pN0, M0 breast cancer (BC) patients (pts). , 2015, , .		0
34	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	1.1	9
35	Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers. International Journal of Radiation Oncology Biology Physics, 2014, 90, S769.	0.4	0
36	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 557-557.	0.8	3

#	Article	IF	Citations
37	Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience. Tumori, 2014, 100, 605-11.	0.6	4
38	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a â€œstandard chemotherapy regimenâ€: The CASA randomized trial. Breast, 2013, 22, 130-137.	0.9	48
39	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of Oncology, 2012, 23, 1436-1441.	0.6	31
40	Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2012, 83, 422-431.	2.0	6
41	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. Tumori, 2012, 98, 33-38.	0.6	4
42	Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?. Archives of Gynecology and Obstetrics, 2012, 285, 499-503.	0.8	0
43	Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. Tumori, 2012, 98, 33-8.	0.6	4
44	Therapeutic management of breast cancer in the elderly. Expert Opinion on Pharmacotherapy, 2011, 12, 945-960.	0.9	15
45	Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer.. Journal of Clinical Oncology, 2011, 29, 282-282.	0.8	3
46	Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.. Journal of Clinical Oncology, 2011, 29, 568-568.	0.8	0
47	Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy, 2010, 33, 735-741.	1.2	11
48	Hormone therapy in elderly breast cancer patients with comorbidities. Critical Reviews in Oncology/Hematology, 2010, 73, 92-98.	2.0	20
49	Interferon-alpha for maintenance of follicular lymphoma. The Cochrane Library, 2010, , CD004629.	1.5	15
50	Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience.. Journal of Clinical Oncology, 2010, 28, 1082-1082.	0.8	5
51	Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience.. Journal of Clinical Oncology, 2010, 28, 1145-1145.	0.8	53
52	Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. European Archives of Oto-Rhino-Laryngology, 2009, 266, 719-726.	0.8	10
53	Can the caregiver replace his/her elderly cancer patient in the physicianâ€“patient line of communication?. Supportive Care in Cancer, 2008, 16, 1157-1162.	1.0	10
54	Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study. Lung Cancer, 2008, 60, 240-245.	0.9	24

#	Article	IF	Citations
55	Pemetrexed in second-line treatment in advanced NSCLC: An experience on 131 patients. Journal of Clinical Oncology, 2008, 26, 19114-19114.	0.8	0
56	Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2007, 55, 125-127.	0.9	5
57	What elderly cancer patients want to know? Differences among elderly and young patients. Psycho-Oncology, 2007, 16, 365-370.	1.0	41
58	Ca-15.3 antigen as predictor of response to EGFR inhibitors in patients with bronchiolo-alveolar carcinoma. Journal of Clinical Oncology, 2007, 25, 18151-18151.	0.8	0
59	Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. Annals of Oncology, 2006, 17, 1335-1336.	0.6	0
60	Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Critical Reviews in Oncology/Hematology, 2005, 53, 125-131.	2.0	17
61	Cancer and aging: are there any differences in the information needs of elderly and younger patients? Results from an Italian observational study. Annals of Oncology, 2005, 16, 1982-1983.	0.6	10
62	P-451 HIV-protease inhibitors as antitumoral therapy in advanced NSCLC patients. Lung Cancer, 2005, 49, S235.	0.9	0
63	Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days. Lung Cancer, 2005, 49, 417-418.	0.9	3
64	Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study. Tumori, 2004, 90, 285-288.	0.6	33
65	Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Annals of Oncology, 2004, 15, 1576.	0.6	9
66	New oral drugs in older patients: a review of idarubicin in elderly patients. Critical Reviews in Oncology/Hematology, 2004, 49, 153-163.	2.0	29
67	Treatment of older breast cancer patients with high recurrence risk. Critical Reviews in Oncology/Hematology, 2003, 46, 241-246.	2.0	8
68	Ifosfamide in Advanced/Disseminated Breast Cancer. Oncology, 2003, 65, 55-58.	0.9	11
69	Nail Toxicity Related to Weekly Taxanes: An Important Issue Requiring a Change in Common Toxicity Criteria Grading?. Journal of Clinical Oncology, 2002, 20, 4404-4405.	0.8	23
70	Idarubicin. Tumori, 2002, 88, S73-S74.	0.6	2
71	Breast Cancer and Pregnancy. Tumori, 2002, 88, 187-192.	0.6	6
72	Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Annals of Oncology, 2000, 11, 1041-1044.	0.6	16

#	Article	IF	Citations
73	Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treatment Reviews, 1996, 22, 223-244.	3.4	14